Drug recall · July 19, 2017
BRILINTA recall
Why: Presence of Foriegn Tablets/Capsules: customer complaint that an 8-count professional sample bottle labeled as BRILINTA 90 mg tablets contained 5 ZURAMPIC 200 mg tablets, in addition to the expected 8 BRILINTA tablets.
Class I: a reasonable chance the product could cause serious harm or death.
The recall
- Product
BRILINTA (ticagrelor) tablets, 90 mg, 8-count Professional Sample bottles, Rx only, Mfd. for: AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850; By: AstraZeneca AB, SE-151 85 Sodertalje, Sweden, NDC 0186-0777-08.
- Lots / codes
Lot # JB5047, Exp 10/19
- Quantity
- 40,368 bottles
- Company
- AstraZeneca Pharmaceuticals, LP, Newark, DE
- Distribution
- Nationwide in the USA and Puerto Rico to physician offices.
- Initiated
- May 25, 2017 · Voluntary: Firm initiated
- Classified
- July 11, 2017
- Reported
- July 19, 2017
- Ended
- April 24, 2018
- How notified
- Press Release
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Brilinta
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.